{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:02:26Z","timestamp":1763445746778,"version":"3.30.2"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Unfractionated heparin (UFH) is frequently administered before percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI). Current guidelines, however, do not provide clear recommendations for UFH pretreatment before arrival at the coronary catheterization laboratory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between June and July 2023, we systematically searched <jats:italic toggle=\"yes\">PubMed<\/jats:italic>, <jats:italic toggle=\"yes\">Embase<\/jats:italic>, and <jats:italic toggle=\"yes\">Cochrane<\/jats:italic> databases for studies comparing UFH pretreatments in patients with STEMI. A random-effects meta-analysis and meta-regression analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Fourteen studies were included, of which four were randomized clinical trials. A total of 76\u2005446 patients were included: 31\u2005238 in the pretreatment group and 39\u2005208 in the control group. Our meta-analysis revealed lower all-cause mortality for the pretreatment strategy when compared with the control group, albeit with high heterogeneity [pooled odds ratio (OR)\u2005=\u20050.61, 95% confidence interval (CI): 0.49\u20130.76, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.01; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u200577%]; lower in-hospital cardiogenic shock (pooled OR\u2005=\u20050.68, 95% CI: 0.58\u20130.78, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.21; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u200527%) and a higher rate of spontaneous reperfusion events (pooled OR\u2005=\u20051.68, 95% CI: 1.47\u20131.91, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.01; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u200579%). In terms of major bleeding, the UFH pretreatment strategy further revealed a decreased rate of events (pooled OR\u2005=\u20050.85, 95% CI: 0.73\u20130.99, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.40; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005=\u20054%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study suggests that UFH pretreatment in patients with STEMI undergoing primary percutaneous coronary intervention was associated with reduced all-cause mortality, cardiogenic shock, enhancing reperfusion rates while diminishing major bleeding events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001413","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:21:05Z","timestamp":1723126865000},"page":"28-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Heparin pretreatment in ST segment elevation myocardial infarction: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"36","author":[{"given":"Gon\u00e7alo","family":"Costa","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra"},{"name":"Faculdade de Medicina da Universidade de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Resende","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Oliveiros","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina da Universidade de Coimbra"},{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lino","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra"},{"name":"Faculdade de Medicina da Universidade de Coimbra"},{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rog\u00e9rio","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar e Universit\u00e1rio de Coimbra"},{"name":"Faculdade de Medicina da Universidade de Coimbra"},{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"R1-20241218","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC).","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R2-20241218","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2048872617727723","article-title":"Editor\u2019s Choice \u2013 Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial.","volume":"8","author":"Karlsson","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R3-20241218","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/hc3101.093701","article-title":"Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials.","volume":"104","author":"Stone","year":"2001","journal-title":"Circulation"},{"key":"R4-20241218","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199222050-00003","article-title":"Heparin pharmacokinetics and pharmacodynamics.","volume":"22","author":"Kandrotas","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"R5-20241218","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00019501-199809060-00003","article-title":"Confirmation that heparin is an alternative means of promoting early reperfusion.","volume":"9","author":"Braga","year":"1998","journal-title":"Coron Artery Dis"},{"key":"R6-20241218","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ccd.28540","article-title":"Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the TOTAL trial.","volume":"96","author":"Cantor","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"R7-20241218","first-page":"1","article-title":"The effect of heparin administration time on thrombolysis in myocardial infarction flow grade in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.","volume":"18","author":"Fakhr-Mousavi","year":"2022","journal-title":"ARYA Atheroscler"},{"key":"R8-20241218","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.recesp.2012.06.005","article-title":"Early anticoagulation may improve preprocedural patency of the infarct-related artery in primary percutaneous coronary intervention.","volume":"66","author":"Ariza","year":"2013","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R9-20241218","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/ehjacc\/zuab032","article-title":"Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes.","volume":"10","author":"Bloom","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R10-20241218","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1253\/circj.71.862","article-title":"Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty.","volume":"71","author":"Chung","year":"2007","journal-title":"Circ J"},{"key":"R11-20241218","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ccd.29144","article-title":"The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.","volume":"97","author":"d\u2019Entremont","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"R12-20241218","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4244\/EIJ-D-22-00432","article-title":"Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).","volume":"18","author":"Emilsson","year":"2022","journal-title":"EuroIntervention"},{"key":"R13-20241218","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2015.06.009","article-title":"Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty.","volume":"198","author":"Giralt","year":"2015","journal-title":"Int J Cardiol"},{"key":"R14-20241218","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2020.09.058","article-title":"Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: does time matter?","volume":"325","author":"Giralt","year":"2021","journal-title":"Int J Cardiol"},{"key":"R15-20241218","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FJC.0000000000000865","article-title":"Prehospital administration of unfractionated heparin in ST-segment elevation myocardial infarction is associated with improved long-term survival.","volume":"76","author":"Mcginley","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"R16-20241218","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0735-1097(97)00495-6","article-title":"High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the heparin in early patency (HEAP) pilot study.","volume":"31","author":"Verheugt","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R17-20241218","first-page":"39","article-title":"The influence of pre-hospital medication administration in ST-elevation myocardial infarction patients on left ventricular ejection fraction and intra-hospital death.","volume":"17","author":"\u017burowska-Wolak","year":"2021","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"R18-20241218","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/archinte.160.15.2369","article-title":"Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.","volume":"160","author":"Zidane","year":"2000","journal-title":"Arch Intern Med"},{"key":"R19-20241218","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jama.2021.25175","article-title":"Review of cardiogenic shock after acute myocardial infarction.","volume":"327","author":"Dalzell","year":"2022","journal-title":"JAMA"},{"key":"R20-20241218","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2048872612447069","article-title":"Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study.","volume":"1","author":"Zeymer","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R21-20241218","doi-asserted-by":"crossref","DOI":"10.1592\/phco.24.12.103S.36109","article-title":"Heparin overview and issues.","volume":"24","author":"Bussey","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R22-20241218","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1592\/phco.24.12.146S.36107","article-title":"Unfractionated heparin: focus on a high-alert drug.","volume":"24","author":"Niccolai","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R23-20241218","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management.","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T17:00:26Z","timestamp":1734541226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001413","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"type":"print","value":"0954-6928"},{"type":"electronic","value":"1473-5830"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}